Blog

BELLEVUE, WA / ACCESS Newswire / July 10, 2025 / CoreStack, a leading provider of NextGen Cloud Optimization, and Governance and Security, today announced it has earned the Microsoft Solutions Partner designation with Certified Software for Azure, recognizing the company’s proven capabilities in delivering enterprise-grade SaaS solutions on Microsoft Azure.

This designation signifies that CoreStack’s platform has met Microsoft’s highest technical standards for architecture, security, and operational excellence, validating its ability to help customers achieve continuous and autonomous cloud governance across FinOps, SecOps, CloudOps, and Well-Architected Framework Assessments.

“Achieving the Solutions Partner designation with Certified Software for Azure is a major milestone in our strategic alignment with Microsoft,” said Trevor Lawless, Global Director of Cloud Alliances at CoreStack. “It underscores our commitment to delivering secure, scalable, and compliant solutions that help our partners and customers establish confidence in the cloud.”

As a long-standing member of the Microsoft AI Cloud Partner Program (MAICPP), CoreStack is now positioned to deepen its co-sell engagement with Microsoft, access enhanced go-to-market benefits, and reach enterprise customers through the Microsoft commercial marketplace.

To learn more, visit www.corestack.io or find CoreStack on the Azure Marketplace.

About CoreStack

CoreStack is an AI-powered NextGen Cloud Governance and Security platform helping 750+ global enterprises manage over $2 billion in cloud spend. With continuous, autonomous, and scalable governance capabilities across security, compliance, operations, and cost, CoreStack empowers organizations to innovate with confidence. CoreStack is a strategic partner across Azure, AWS, GCP, and Oracle Cloud.

SOURCE: CoreStack Inc.

View the original press release on ACCESS Newswire

Partnership creates geographic advantages aligned with SMA’s strategic growth plan while diversifying the distribution of individual insurance products

NASHVILLE, TENN. AND CLEARWATER, FLA. / ACCESS Newswire / July 10, 2025 / Senior Market Advisors (SMA), a leading insurance marketing organization and an affiliate of AmeriLife, is excited to announce a strategic partnership with Agent Boost Marketing, a premier provider of marketing and technology solutions for insurance agents. This collaboration aims to enhance the capabilities and success of insurance agents by integrating Agent Boost’s advanced tools and support services with Senior Market Advisors’ extensive industry expertise and resources. Per the agreement, terms of the deal were not disclosed.

One of the key advantages of this partnership is Agent Boost’s high-quality, technology-driven platform. The company leverages cutting-edge data analytics and digital marketing strategies to consistently generate a flow of potential clients, which is essential for driving business growth. Meanwhile, SMA’s professional approach to agent support will be available to help navigate the complexities of the insurance market, offering expert guidance and advanced tools to close more sales effectively. This collaboration also provides SMA with a strategic geographic advantage, including a firmly established presence in the West, which aligns with SMA’s broader strategic growth plan and future management needs.

“We are thrilled to partner with Agent Boost Marketing,” said Joshua Borders, CEO, Senior Market Advisors. “This collaboration will empower SMA’s affiliated agents with the tools and support they need to succeed in today’s competitive insurance market. By combining our industry knowledge with Agent Boost’s cutting-edge technology, we are confident that our agents will achieve greater success and provide even better service to their clients.”

This alliance also focuses on comprehensive training and development. Agents will receive regular sales and business training, equipping them with the latest industry knowledge and best practices. The interactive Agent Training Center will serve as a valuable resource, providing ongoing education and professional development opportunities to help agents stay ahead in a rapidly evolving market.

“Senior Market Advisors is a respected leader in the insurance industry, and we are excited to partner with them,” said Dan Hardle, CEO of Agent Boost Marketing. “There are immense synergies that exist between our organizations, and our agents and agency partners are going to greatly benefit from the partnership.”

The SMA partnership provides Agent Boost with access to AmeriLife’s top-tier carrier contracts, which will expand product offerings and provide a greater runway for growth and expansion. SMA’s robust marketing initiatives and consumer education programs will also help generate high-quality leads, driving more business to Agent Boost. The partnership also includes dedicated agent support and world-class training, which can significantly improve the skills and efficiency of Agent Boost’s agents. SMA’s innovative online enrollment platform streamlines the sales and enrollment process.

“We are thrilled to welcome Agent Boost to the expanding suite of services offered by Senior Market Advisors to our partners and their customers,” said Scotty Elliott, Chief Distribution Officer, Health, at AmeriLife. “This partnership will deliver a unique and comprehensive approach to achieving success in a competitive market, fostering substantial business growth and customer satisfaction.”

About Senior Market Advisors
Senior Market Advisors, an AmeriLife company, is a full-service field marketing organization that partners with insurance agencies and their teams of independent agents to provide educational information about Medicare solutions such as Medigap and Medicare Advantage, prescription drug plans, ACA health insurance plans, annuities, and final expense life insurance and a complete product portfolio of lead programs serving an agency’s senior market sales needs. For more information, visit SeniorMarketAdvisors.com.

About Agent Boost Marketing
At Agent Boost, we are dedicated to your success. Our mission is to empower you with an evolving lead pipeline, innovative technology, and professional training, supporting agents across all 50 states and at various experience levels. With years of industry experience, we provide tailored solutions to enhance efficiency and customer satisfaction and have become a trusted partner in the broker community. Our agents receive regular training, mentorship, and specialized instruction on sales strategies and industry products from national leaders. At the heart of our business is a client-first approach, ensuring the highest level of care and service. Partner with Agent Boost to join a network of professionals making a difference, one policy at a time. For more information, visit AgentBoost.com.

About AmeriLife
AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. AmeriLife develops, markets, and distributes life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For over 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers through a national distribution network of over 300,000 agents, financial professionals, and more than 160 marketing organizations and insurance agencies. For more information, visit AmeriLife.com and follow AmeriLife on Facebook and LinkedIn.

SOURCE: AmeriLife

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / July 10, 2025 / Voices, the world’s most comprehensive voice solutions provider, today announced it will officially be launching its new voice data solution during an exclusive virtual product launch event on July 17 at 1pm ET. The solution offers AI builders, tech companies, and brands a responsible and trusted path to power their voice AI strategy.

For the past year, Voices has been quietly working with some of the largest technology companies to power their voice AI with the right voice data, all ethically sourced and properly licensed. Voices is now officially launching their solution.

The launch event will take place on July 17, at 1pm ET. Attendees can expect to:

Learn how Voices is meeting the demand for responsible voice data-and how trust, consent, compensation, and ethics are built into every layer of the solution

Discover how the data is collected, curated, and deployed

Access fresh market insights and get a glimpse of what’s coming next

“High-quality, ethical voice data is scarce, yet it is essential for responsible AI development,” says Blake Hayward, Senior Vice President of Product at Voices. “Voice AI is only as good as the data it’s trained on. That’s why our clients rely on us to provide the best, ethically sourced voice data to train their models. We’re proud to set the industry standard for responsible voice AI.”

Voice AI is quickly becoming the default interface for conversational AI, already taking its form in voicebots, drive-thru assistants, AI customer service agents, and more. But the increased demand for voice AI is challenged by the scarcity of ethical, properly licensed voice data to train voice models.

For two decades, Voices has been the go-to marketplace for brands, agencies, and creatives to discover and hire voice talent. With generative voice AI on the rise, Voices has expanded its services to help customers build voice AI the right way, while offering opportunities for voice talent to participate in and benefit from the evolving landscape.

To learn more about how Voices is powering ethical voice AI, visit: https://www.voices.com/landing/voice-data-launch.

About Voices

Voices is the world’s leading enterprise-class marketplace and platform to ethically source voice over actors, voice AI, and voice data to train AI models. For more than two decades, the world’s biggest brands, like Shopify, Microsoft, and Cisco, have trusted Voices to ‘find their voice’. The Voices talent base is composed of many millions of actors across the globe, who trust Voices to support their interests and help them find meaningful work.

Media Contact: Patrice Aldave | patrice.aldave@voices.com | 519-858-4224

Contact Information:

Patrice Aldave
PR Specialist
patrice.aldave@voices.com
519-858-4224

Contact Information:

Patrice Aldave
PR Specialist
patrice.aldave@voices.com
519-858-4224

SOURCE: Voices

View the original press release on ACCESS Newswire

Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia^®, conditionally approved for CID, to regulatory approval and commercialization for general diarrhea globally

Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs

Jaguar CEO Lisa Conte presenting July 17 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register

SAN FRANCISCO, CA / ACCESS Newswire / July 10, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), under its Jaguar Animal Health tradename for the veterinary market, today announced that four dogs have now been enrolled in Jaguar’s ongoing field study of Canalevia-CA1, the company’s U.S. Food and Drug Administration (FDA) conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs, and enrollment is continuing. Six veterinary oncology clinics have signed on to take part in this study, and Jaguar is in discussions with other veterinary oncology clinics regarding possible participation.

“Jaguar’s primary objective for Canalevia (crofelemer delayed-release tablets) is to identify a partner with which to collaborate to achieve our three parallel goals for the drug: Obtain approval in the European Union for Canalevia for treatment of general diarrhea in dogs based on existing Jaguar study data; maintain continuity of availability in the U.S. of Canalevia for treatment of CID in dogs; and to expand the U.S. indication from CID in dogs to treatment of general diarrhea in dogs,” said Lisa Conte, Jaguar’s Founder and CEO. “I’m pleased to report that Jaguar is currently in discussions with multiple potential animal health company partners to collaborate to bring Canalevia to regulatory approval and commercialization for general diarrhea globally.”

Canalevia contains crofelemer, a plant-based botanical prescription drug that modulates chloride channels in the gastrointestinal tract to reduce diarrhea. Importantly, Canalevia is not an antibiotic drug. The overuse and misuse of antibiotics, both in humans and animals, contribute to the development of bacteria that are resistant to antibiotics.

“In the EU, as we announced, it may be possible to obtain approval of Canalevia for treatment of general diarrhea in dogs based on the results of a study Jaguar completed in 200 dogs with general diarrhea,” Conte said. “While this completed trial did not meet its stated primary endpoint, the study results are clinically significant when analyzed using an alternate, simplified endpoint, defining treatment success as any dog that had no episodes of diarrhea following the first treatment with either Canalevia or placebo. Using this revised endpoint, the study data shows that dogs treated with Canalevia had significantly better outcomes – with fewer watery stools and significant improvement in fecal scores compared to placebo-treated dogs.”

Jaguar plans to submit a dossier to the European Medicines Agency (EMA) to outline the results of the updated analysis of the company’s completed study of Canalevia in dogs with general diarrhea. If acceptable to the EMA, the company will then submit a Marketing Authorization Application (MAA) for Canalevia for general diarrhea in dogs. If the application is approved, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries.

Data from the European Pet Food Industry Federation concluded that there were 104 million dogs in Europe in 2022. “We’ve been pleased with the marketplace reception of crofelemer for treatment of CID in dogs in the U.S. and believe there is clearly an unmet medical need for a product for the much larger market of treatment of general diarrhea in dogs – both in the U.S. and the EU,” said Conte. “We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs, and we look forward to identifying a partner to fund and execute development and commercialization of crofelemer for the treatment of general diarrhea in the U.S. and/or globally. Forging a partnership for this purpose is a key focus of our business development efforts in 2025 and has been designated as a key potential catalyst for the company this year.”

Diarrhea is one of the most common reasons dogs are seen by general practice veterinarians and is the second most common reason for visits to veterinary emergency hospitals, yet there is currently no FDA-approved drug to treat general, non-infectious diarrhea in dogs. According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the United States in 2024, with nearly half (45.5%) of U.S. households owning a dog in 2024. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of easy access to outdoor facilities is a significant problem for families living in urban settings with dogs.

Canalevia-CA1, a canine-specific formulation of crofelemer, Jaguar’s novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is available from multiple leading veterinary distributors in the U.S., including Chewy.

The objective of the ongoing, prospective, randomized, open-label field study in dogs undergoing chemotherapy treatment across the U.S. is to collect real-world data to demonstrate real-world evidence of the clinical effectiveness for Canalevia-CA1 for the treatment of CID in dogs to support potential full FDA approval of the drug for this indication. Dogs enrolled in this study will be randomly assigned to receive a prescription of Canalevia-CA1 as a treatment for CID or be randomly selected to the control group.

Participation Instructions for Jaguar’s Virtual Presentation at the Emerging Growth Conference

When: Thursday, July 17, 2025 from 2:55 – 3:05 PM Eastern

Where: Online (Click Here)

Registration link for conference: Click Here

Replay: An archived webcast of the presentation will be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel.

About Conditional Approval and Full Approval

Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA’s conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the “substantial evidence” standard of effectiveness for full approval. The conditional approval is valid for one year. The drug company can ask the FDA to renew the conditional approval annually for up to four more years, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving “substantial evidence of effectiveness” for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.

About Chemotherapy-induced Diarrhea (CID) in Dogs

According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost 50% of dogs over age 10 will develop cancer.¹ According to the National Cancer Institute, which is part of the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs each year in the U.S.

Due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,² and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.

Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs.

About Canalevia^®-CA1

Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a “small number” threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use.

About Crofelemer

Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.

Important Safety Information About Canalevia^®-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Canalevia-CA1, visit canalevia.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that Jaguar management will present at the July 2025 Emerging Growth Conference, Jaguar’s expectation that it will identify a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S and/or globally, Jaguar’s expectation that it may be possible to obtain approval of Canalevia in the EU for treatment of general diarrhea in dogs based on the results of a study Jaguar completed in 200 dogs with general diarrhea, Jaguar’s expectation that it will submit a dossier to the EMA to outline the results of the updated analysis of the company’s completed study of Canalevia in dogs with general diarrhea, Jaguar’s expectation that, if the submitted dossier is acceptable to the EMA, the company will then submit a MAA to the EMA for Canalevia for general diarrhea in dogs, and Jaguar’s expectation that the field study of Canalevia-CA1 for the treatment of CID in dogs will support potential full FDA approval of the drug for this indication. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

¹ “Cancer in Pets.” American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets

² Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

Menlo Ventures leads round backing intelligent assistants that help tax firms scale amid rising workloads and shrinking headcount.

SAN FRANCISCO, CA / ACCESS Newswire / July 10, 2025 / Abacus, the company developing agentic CPA assistants for modern accounting firms, today announced it has raised $6.6 million in seed funding. The round was led by Menlo Ventures, with significant participation from Pear VC and participation from Recall Capital, and Original Capital. The funding will accelerate Abacus’ mission to give CPAs superpowers – turning junior-level preparers into reviewers and bringing Big Four-level automation and efficiency to the entire CPA market. Their intelligent assistants learn firm-specific workflows and take on the rote, high-volume tasks that slow teams down.

Founded by brothers Cody Sugarman (CEO) and Brandon Sugarman (CTO), both engineers from Stanford, Abacus brings an AI-first approach to modernizing how accounting firms operate.

As accounting firms face mounting pressure from shrinking headcount and growing client demands, Abacus helps teams stay efficient, eliminating repetitive manual work while maintaining the precision and control tax firms need.

“With fewer professionals entering the field and workloads rising, the accounting industry is under immense pressure,” said Cody Sugarman. “We’re seeing an explosion of BPO usage, but associates are still working 60+ hour weeks during the busy seasons to meet the April and October deadlines. We’re building software that doesn’t just automate tasks-it works alongside teams, adapts to how they operate, and scales with their complexity. This funding allows us to expand our platform and bring this new category of assistant to more firms across the industry.”

Abacus is starting where the impact is highest: automating data entry, the most expensive and time-consuming task in the tax preparation process. Today, tax associates spend up to 80% of their time on manual rote tasks like data collection and reconciliation, and preparing workpapers before a CPA ever sees the return. With fewer professionals entering the field and increasing pressure on delivery timelines, many firms are turning to offshore teams, paying $30 or more per return and facing long turnaround times during peak season.

“The idea for Abacus came from our own CPA issuing us a ‘7216 consent form’, essentially telling us that the bulk of our tax prep work was going to be offshored,” said Brandon Sugarman. “This sparked a curiosity in the industry and eventually led to our first paying customer.”

The platform automates data collection by pulling from client documents, past returns, and standard forms-no 7216 consent form required-and classifies, reconciles, and pushes data directly into CPA workflows for review and filing. What once took hours of back-and-forth and manual entry can now be done 10x faster and at a fraction of the cost, with no bottlenecks during crunch time.

“Accounting is one of the last major service industries still bogged down by 30-year old legacy systems and manual workflows,” said Croom Beatty, Partner at Menlo Ventures. “With more than half of accountants expected to retire in the next decade, there is an acute need for AI to reshape and improve how modern accounting gets done. Cody and Brandon have a deep understanding of the intricacies and nuances of how accounting firms operate and have built a powerful tax product that allows best in class accounting firms to better serve their end customers.”

Abacus is currently expanding its team and hiring across several roles. Those interested can learn more at getabacus.com or reach out directly to cody@getabacus.com.

ABOUT ABACUS:

Abacus builds agentic infrastructure for accounting firms. Founded by brothers and Stanford engineers, Cody and Brandon Sugarman, Abacus is rethinking how high-trust industries adopt intelligent software: not through flashy interfaces, but through deeply embedded, domain-specific automation. For more, visit getabacus.com.

MEDIA CONTACT:

Lauren Gill, MAG PR at E: lauren@mooringadvisorygroup.com; P: 978-473-1362

SOURCE: Abacus

View the original press release on ACCESS Newswire

Report details progress in Environmental, Social, and Governance priorities and strengthens investor transparency

The full ESG report is available: HERE

To view Brenmiller’s latest investor deck please click: HERE

DIMONA, IL / ACCESS Newswire / July 10, 2025 / Brenmiller Energy Ltd. (Nasdaq:BNRG), a leading global provider of Thermal Energy Storage (“TES”) solutions for industrial and utility customers, announced today it has published its annual Environmental, Social, and Governance (ESG) Report. The 2024 report reflects a pivotal year in the Company’s transition from pilot-scale validation to full-scale commercial execution, and its expanding commitment to sustainable operations across its value chain.

“This report reflects a year of execution, impact, and maturity as we position Brenmiller as a global TES leader,” said Avi Brenmiller, Chairman and Chief Executive Officer. “We are not only helping our customers reach their net-zero goals, but are also aiming to set a benchmark for ESG performance in the clean energy sector.”

The report outlines how Brenmiller is executing its multi-year ESG roadmap (2023-2026), strengthening climate risk integration, and advancing full carbon emissions tracking in accordance with its greenhouse gas (“GHG”) Protocol and Task Force for Climate-Related Financial Disclosures (“TCFD”).

Key Strategic Highlights

• Strategic Shift to Commercialization: Transitioned from pilot-scale projects to commercial installations with global collaborations including Tempo Beverages, Wolfson Hospital, and Partner in Pet Food Hungaria KFT.

• European Expansion: Established a Spain-based joint venture, Brenmiller Europe S.L., to lead regional marketing, engineering, procurement, and project execution in Europe.

• Environmental Innovation through Automation: Advanced lean manufacturing processes at the TES gigafactory have reduced scrap generation and improved energy efficiency.

• Climate Risk Integrated into Risk Management: Climate-related risks now formally included in enterprise risk assessments and ESG governance.

• Expanded GHG Tracking: Full Scope 1 and 2 emissions tracked in 2024; Scope 3 data collection in progress with full coverage expected by end of 2025.

• Continued Execution of ESG Roadmap (2023-2026): Regular performance monitoring aligned with risk management and long-term strategy.

ESG Category Highlights

Environmental (E):

• Gigafactory Milestone: Operationalized the world’s first TES gigafactory; at full capacity, it can reach 4 GWh of annual production.

• GHG Reduction Potential: At full production capacity, TES manufacturing is estimated to result in approximately 38,000 tons of CO₂e emissions annually.

• Eco-Efficient Production: Rock-drying with solar power, new dust collection system, and waste recycling integrated into factory processes.

Social (S):

• Zero Workplace Accidents: Maintained an incident-free safety record in 2024, with 12+ hours of training per manufacturing employee.

• 100% Staff Training Completion: All employees completed training in safety, compliance, and professional development.

• Community Engagement: Supported hospitals, kindergartens, and elder care facilities in Dimona through employee-led initiatives.

Governance (G):

• Board Strength and Independence: 86% of board members have prior public board experience; 57% bring cleantech or energy expertise.

• Robust ESG Oversight: ESG risks managed under the Company’s Enterprise Risk Management (“ERM”) program and monitored by the Audit Committee of the Company’s Board of Directors.

• Strong Ethics Culture: Code of Conduct, Insider Trading Policy, and Anti-Corruption compliance enforced across the organization.

Continued ESG Commitment

Brenmiller Energy views ESG as a core pillar of its business strategy and long-term value creation. The Company remains committed to continuous improvement and will continue working toward the ambitious ESG goals outlined in its 2023-2026 roadmap. ESG performance will remain a key driver of Brenmiller’s innovation, risk management, and stakeholder engagement in the years ahead.

About Brenmiller Energy Ltd.

Brenmiller Energy helps energy-intensive industries and power producers end their reliance on fossil fuel boilers. Brenmiller’s patented bGen™ ZERO thermal battery is a modular and scalable energy storage system that turns renewable electricity into zero-emission heat. It charges using low-cost renewable electricity and discharges a continuous supply of heat on demand and according to its customers’ needs. The most experienced thermal battery developer on the market, Brenmiller operates the world’s only gigafactory for thermal battery production and is trusted by leading multinational energy companies. For more information visit the Company’s website at https://bren-energy.com/ and follow the company on X and LinkedIn.

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements when discussing the Company’s position as a global TES leader; that the Company will set a benchmark for ESG performance in the clean energy sector; that the Company will reach full carbon emissions tracking in line with GHG Protocol and TCFD; the Company’s ability to reach Scope 3 emissions data collection with full coverage expected by end of 2025; the Company’s execution of the ESG roadmap; that the TES gigafactory will reach 4 GWh of annual production at full capacity; that at full production capacity, TES manufacturing is estimated to result in approximately 38,000 tons of CO₂e emissions annually; and that the ESG performance will remain a key driver of innovation, risk management, and stakeholder engagement. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect the Company’s results include, but are not limited to: the Company’s planned level of revenues and capital expenditures; risks associated with the adequacy of existing cash resources; the demand for and market acceptance of our products; impact of competitive products and prices; product development, commercialization or technological difficulties; the success or failure of negotiations; trade, legal, social and economic risks; and political, economic and military instability in the Middle East, specifically in Israel. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 4, 2025, which is available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact: investors@bren-energy.com

SOURCE: Brenmiller Energy

View the original press release on ACCESS Newswire

Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease

CAMBRIDGE, MA / ACCESS Newswire / July 10, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Spikevax®, the Company’s COVID-19 vaccine, in children 6 months through 11 years of age who are at increased risk for COVID-19 disease. The Company’s COVID-19 vaccine, mRNA-1273, was previously available for pediatric populations under Emergency Use Authorization (EUA).

“COVID-19 continues to pose a significant potential threat to children, especially those with underlying medical conditions. Vaccination can be an important tool for protecting our youngest against severe disease and hospitalization,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We appreciate the FDA’s diligent scientific review and approval of Spikevax for pediatric populations at increased risk for COVID-19 disease.”

Moderna expects to have its updated Spikevax vaccine available for eligible populations in the U.S. for the 2025-2026 respiratory virus season.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Spikevax® is a registered trademark of Moderna.

INDICATION

SPIKEVAX (COVID-19 Vaccine, mRNA) is a vaccine to protect you against COVID-19. SPIKEVAX is for people who are:

• 65 years of age and older, or

• 6 months through 64 years of age at high risk for severe COVID-19.

Vaccination with SPIKEVAX may not protect all people who receive the vaccine.

IMPORTANT SAFETY INFORMATION

You or your child should not get SPIKEVAX if you had a severe allergic reaction after a previous dose of SPIKEVAX or any Moderna COVID-19 vaccine or to any ingredient in these vaccines.

What are the risks of SPIKEVAX?

There is a very small chance that SPIKEVAX could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of SPIKEVAX. For this reason, the healthcare provider may ask you or your child to stay for a short time at the place where you or your child received your vaccine. Signs of a severe allergic reaction can include:

• Trouble breathing

• Swelling of your face and throat

• A fast heartbeat

• A rash all over your body

• Dizziness and weakness

• Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines. Myocarditis and pericarditis following mRNA COVID-19 vaccines have occurred most commonly in males 12 years through 24 years of age. You should seek medical attention right away if you or your child has any of the following symptoms after receiving Spikevax, particularly during the 2 weeks after receiving a dose of the vaccine: chest pain, shortness of breath, feelings of having a fast-beating, fluttering, or pounding heart. Additional symptoms in children may include fainting, irritability, poor feeding, lack of energy, vomiting, pain in the abdomen, or cool, pale skin.

Other side effects that have been reported include:

• Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection or in the groin, swelling (hardness), and redness

• General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea and vomiting, fever, rash, irritability/crying, sleepiness, and loss of appetite.

• Fainting and febrile seizures (convulsions during a fever) were also reported

Tell the healthcare provider about all of your or your child’s medical conditions, including if you or your child:

• have any allergies

• had a severe allergic reaction after receiving a previous dose of any COVID-19 vaccine

• have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)

• have a fever

• have a bleeding disorder or are on a blood thinner

• are immunocompromised or on a medicine that affects your immune system

• are pregnant or plan to become pregnant

• are breastfeeding

• have received any other COVID-19 vaccine

• have ever fainted in association with an injection

These may not be all the possible side effects of SPIKEVAX. Ask your healthcare provider about any side effects that concern you. You may report side effects to Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or http://vaers.hhs.gov.

Please see the SPIKEVAX Full Prescribing Information.

Moderna Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the availability of an updated Spikevax vaccine for eligible populations in the U.S. for the 2025-2026 respiratory virus season. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

INDIANAPOLIS, IN AND COSTA MESA, CA / ACCESS Newswire / July 10, 2025 / Arrive AI (NASDAQ:ARAI) – a pioneering autonomous delivery network anchored by Arrive Points™ – has selected Synoptek as a strategic IT partner to enable its rapid growth and global ambitions. Synoptek will provide Arrive AI with all the IT solutions it needs to support its business.

With a recent injection of up to $40 million in funding from Streeterville Capital, Arrive AI is entering a critical growth phase. The company is preparing to launch its patented, autonomous delivery platform later this summer and expects to triple its staff size.

“Synoptek’s strategic approach, deep expertise, robust tech stack and strong partnerships with Microsoft and ServiceNow made it a clear choice,” said Mark Hamm, COO of Arrive AI. “We were searching for a partner who could move at our pace and help us build a resilient IT foundation for global expansion. After conducting an exhaustive search, we knew Synoptek would be the partner we were looking for to provide all of IT capabilities we need to take our business to the next level”

Under the three-year agreement, Synoptek will contribute to the solution definition, implementation and IT management, including, cybersecurity, enterprise-grade IT and 24/7 AI-enabled managed services operations. This engagement deepens Synoptek’s presence in the high-growth logistics and manufacturing sector and aligns with its mission to deliver smart, secure and connected IT environments.

“We’re proud to serve as an extension of the Arrive AI team,” said Salil Godika, CEO at Synoptek. “Together, we are building a resilient and secure IT backbone that supports innovation and scale. We deliver focused solutions that incorporate exceptional customer experiences, digital application engineering, and agile infrastructure. We are committed to providing Arrive AI with the technology foundation it needs to grow with confidence.”

Synoptek will provide advisory services and information sharing around security, AI and application innovation as Arrive AI continues to push boundaries in the AI transportation and logistics space.

-30-

About Arrive AI: Arrive AI’s patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox, whether by drone, ground robot or human courier. The platform provides real-time tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting and security systems to streamline the entire last-mile delivery experience. Learn more at www.arriveai.com.

Media contact: Cheryl Reed at media@arriveai.com

Investor Relations Contact: Alliance Advisors IR at ARAI.IR@allianceadvisors.com

About Synoptek: Synoptek is a global, full-service business and digital technology solutions provider and advisory firm that helps companies envision, transform, and evolve their customer experiences, application ecosystems, and infrastructures. As a systems integrator and managed technology provider, Synoptek partners with organizations worldwide, helping them navigate the ever-changing technology landscape and build solid tech foundations for their businesses.

With its comprehensive offerings, global workforce, and strategic technology partnerships, Synoptek helps companies optimize their IT environments and enable innovation through technology. With growth, ownership, inclusiveness, and philanthropy embedded in its DNA, Synoptek is committed to delivering improved business results and unmatched service to all its stakeholders.

Cautionary Note Regarding Forward Looking Statements

This news release and statements of Arrive AI’s management in connection with this news release or related events contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements (including statements related to the closing, and the anticipated benefits to the Company, of the private placement described herein) related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would”, “optimistic” or “may” and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Arrive AI’s Registration Statement for more complete information, including the risk factors that may affect future results, which are available for review at www.sec.gov. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

SOURCE: Arrive AI Inc.

View the original press release on ACCESS Newswire

Latest battery systems feature enhanced performance and include 54Ah ceramic cell to be mass produced in Jamestown, NY

Passed the most stringent safety testing in the industry, including fire propagation testing

Further strengthens the Company’s leadership position in the market for industrial and heavy duty vehicles

TORONTO, ON / ACCESS Newswire / July 10, 2025 / Electrovaya Inc. (“Electrovaya” or the “Company”) (NASDAQ:ELVA)(TSX:ELVA), a leading lithium-ion battery technology and manufacturing company, is pleased to announce that it has successfully completed UL2580 certification for 448 distinct models of its latest generation 24V, 36V, and 48V lithium-ion battery systems. The certification includes battery systems composed of its current 47Ah cell in addition to its 54Ah cell which will be mass produced at its facility in Jamestown, New York in 2026. The next generation models feature improved charge rates, energy density, ergonomics and overall performance. Notably, the new models also provide the highest energy densities of batteries used in the material handling industry, providing an additional competitive advantage. These next generation battery systems will start being made available to customers this year.

The UL2580 certification involved some of the most stringent safety testing standards in the industry and included fire propagation testing, vibration, shock and short circuit testing amongst other destructive testing.

“This is an important milestone as we prepare to launch our next generation of products for one of our key industrial markets,” said Dr. Raj DasGupta, CEO of Electrovaya. “The UL2580 certification is one of the most trusted safety benchmarks in the battery industry and underscores the strength of the safety capabilities of our Infinity battery technology. The material handling industry represents a large portion of our revenue and with our significant advancements made for our next generation products, we expect to further strengthen our leadership position in the market.”

Investor and Media Contact:

Jason Roy
VP, Corporate Development and Investor Relations
Electrovaya Inc.
905-855-4618 / jroy@electrovaya.com

About Electrovaya Inc.

Electrovaya Inc. (NASDAQ:ELVA) (TSX:ELVA) is a pioneering leader in the global energy transformation, focused on contributing to the prevention of climate change by supplying safe and long-lasting lithium-ion batteries. The Company has extensive IP and designs, develops and manufactures proprietary lithium-ion batteries and battery systems for energy storage and heavy duty electric vehicles based on its Infinity Battery Technology Platform. This technology offers enhanced safety and industry leading battery longevity. The Company is also developing next generation solid state battery technology at its Labs division. Headquartered in Ontario, Canada, Electrovaya has two operating sites in Canada and has acquired a 52-acre site with a 135,000 square foot manufacturing facility in New York state for its planned gigafactory. To learn more about Electrovaya, please explore www.electrovaya.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to announcements regarding cell performance, cycle life, longevity, projected performance, extrapolated cycle life, energy density, relative performance compared to competitors, planned production in Jamestown New York, ability to start production in Jamestown in the expected timeframe, planned 54Ah lithium-ion ceramic cell in product lines in 2025 and 2026, use in commercial vehicle and energy storage applications, energy density, cell performance, safety, cost of ownership, life cycle cost, and can generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective”, “seed”, “growing” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors and assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Statements with respect to solid state batteries, battery technologies and production roadmaps, are based on an assumption that the Company’s customers and users will deploy its products in accordance with communicated intentions, and the Company has investment capital to deploy. Important factors that could cause actual results to differ materially from expectations include but are not limited to macroeconomic effects on the Company and its business and on the Company’s customers, including inflation and tightening credit availability due to systemic bank risk, economic conditions generally and their effect on consumer demand and capital availability, labour shortages, supply chain constraints, the potential effect of health based restrictions in Canada, the US and internationally on the Company’s ability to produce and deliver products, and on its customers’ and end users’ demand for and use of products, which effects are not predictable and may be affected by additional regional outbreaks and variants, and other factors which may cause disruptions in the Company’s supply chain and Company’s capability to deliver and develop its products. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s Annual Information Form for the year ended September 30, 2024 under “Risk Factors”, and in the Company’s most recent annual Management’s Discussion and Analysis under “Qualitative And Quantitative Disclosures about Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: Electrovaya, Inc.

View the original press release on ACCESS Newswire

New hire supports operational scale-up and financial infrastructure as company ramps U.S. motor manufacturing

ORLANDO, FLORIDA / ACCESS Newswire / July 9, 2025 / Unusual Machines, Inc. (NYSE American:UMAC), a leader in drone technology and component manufacturing, today announced the appointment of Tim Manton, CPA, as Corporate Controller, reporting to Chief Financial Officer Brian Hoff. Manton brings more than 15 years of experience in financial operations, M&A, and reporting across high-growth and acquisition-driven companies.

“Tim brings strong financial acumen and experience critical to dynamic, scaling environments,” said Hoff. “His background in M&A, systems integration, and financial oversight makes him a valuable addition as we sharpen our focus on execution and operational efficiency.”

Manton most recently served as Director of Finance and Accounting at Sony Electronics (formerly KinaTrax), where he helped lead the company through a strategic acquisition. His prior roles at Blue Force Technologies and Ultra Electronics included ERP transitions, public company reporting, and post-merger financial integration.

The appointment comes as Unusual Machines scales its domestic operations, including a 17,000-square-foot motor production facility in Orlando, Florida. The company is actively building out its financial and operational infrastructure to support U.S.-made components, including high-performance drone motors designed to meet growing regulatory and customer demand.

“Strong financial systems are the foundation of any growing business,” Hoff added. “Tim’s leadership will be instrumental as we invest in the people, processes, and platforms that support disciplined growth and a competitive U.S. manufacturing strategy.”

Please visit: unusualmachines.com/careers the company’s latest job opportunities.

About Unusual Machines

Unusual Machines manufactures and sells drone components and drones across a diversified brand portfolio, which includes Fat Shark, the leader in FPV (first-person view) ultra-low latency video goggles for drone pilots. The company also retails small, acrobatic FPV drones and equipment directly to consumers through the curated Rotor Riot ecommerce store. With a changing regulatory environment, Unusual Machines seeks to be a dominant Tier-1 parts supplier to the fast-growing multi-billion-dollar U.S. drone industry. According to Fact.MR, the global drone accessories market is currently valued at $17.5 billion and is set to top $115 billion by 2032.

For more information, visit unusualmachines.com

Investor Contact:

CS Investor Relations
investors@unusualmachines.com

Media Contact
media@unusualmachines.com

SOURCE: Unusual Machines

View the original press release on ACCESS Newswire